INTRODUCTION
============

Described by Muir *et al* and Torre, Muir-Torre Syndrome (MTS) is a rare autosomal dominant condition with a high degree of penetrance.^[@r01],[@r02]^ In 1995, diagnostic criteria for the syndrome were proposed by Schwartz and Torre, which included the presence of a sebaceous tumor (sebaceous adenoma, sebaceous carcinoma or sebaceoma) and at least one visceral malignancy.^[@r03]^

Currently, it is believed that there are two types of MTS. The most common form is a variant of Hereditary Nonpolyposis Colorectal Cancer or Lynch Syndrome, associated with germline mutations in DNA repair genes encoders of proteins *MutL Homolog 1 (MLH1)* and *MutS Homolog 2 (MSH2)*. Recently, mutations in genes of proteins *MutS Homolog 6 (MSH6)* and *Postmeiotic Segregation Increased 2 (PMS2)* were also implicated. The other spectrum of the disease, however, has no correlation with family history and seems to involve other genes than the DNA repairing ones.^[@r04],[@r05]^

In this article, the authors report the case of a male patient with multiple sebaceous tumors and history of colorectal carcinoma. The immunohistochemical study of the cutaneous neoplasm was used to corroborate the diagnosis of Muir-Torre Syndrome, revealing the expected negativity for DNA repair enzymes.

CASE REPORT
===========

Male patient, 41 years old, presented at the Dermatology service complaining about the onset of multiple yellowish papules with central umbilication located on the face ([Figures 1](#f01){ref-type="fig"} and [2](#f02){ref-type="fig"}). The anatomopathological examination was conclusive for sebaceous adenoma ([Figure 3](#f03){ref-type="fig"}). An immunohistochemical study was performed through a standard technique, with parts (sugestão: tissue pieces) in paraffin blocks and histological sections incubated with a panel of monoclonal antibodies. A polymer-based detection system was used. The antibodies used were repair enzymes *MSH2*, *MSH6* and *MLH1,* with nuclear negativity occurring for *MSH2* and *MSH6* and inconclusive *MLH1* search ([Figures 4](#f04){ref-type="fig"} and [5](#f05){ref-type="fig"}).
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![Immunohistochemical examination: sebaceous adenoma revealing nuclear negativity for repair enzyme MSH2](abd-90-03-s1-0168-g04){#f04}

![Immunohistochemical examination: sebaceous adenoma in a positive control patient showing preserved nuclear reactivity for repair enzyme MLH1](abd-90-03-s1-0168-g05){#f05}

DISCUSSION
==========

The most frequent MTS subtype is the phenotypic spectrum of Lynch syndrome, in which mutations of DNA repair genes can be detected.

The DNA repairing system is critically important to maintain genome stability during DNA replication. Failure in this process results in mutation of genetic material and microsatellite instability. For example, the loss of expression of the protein coded by gene *MSH2* leads to the accumulation of replication errors, which ultimately is related to tumor susceptibility. ^[@r06],[@r07]^

MTS mutations predispose for the onset of cutaneous tumors of sebaceous origin. Notwithstanding, the mechanism through which the loss of repairing proteins and microsatellite instability result in this type of tumor has not yet been elucidated.^[@r08]^

In general, sebaceous tumors are rare in the population, and for this reason their onset represents an important marker for investigation of the syndrome.^[@r09]^ The most frequently found cutaneous neoplasms are sebaceous adenoma, sebaceous carcinoma and sebaceoma, which are usually subsequent to the diagnosis of visceral carcinoma in 56% of the cases. Keratoacanthomas and non-melanoma skin carcinomas are also described with sebaceous differentiation in the carriers of the disease.^[@r04]^

As to visceral neoplasms, colorectal carcinomas account for 51% of the cases. Malignancies of the genitourinary system, breast, lungs, parotid gland, upper gastrointestinal tract, larynx and blood may be present, although rarely. The follow-up of these patients is comprised of colonoscopy every 3-5 years, starting at 25-30 years of age, cystoscopy and intravenous pyelogram at regular intervals, computed tomography of the abdomen and pelvis every 2-5 years, yearly mammogram and endometrial biopsy every 3-5 years in women over 50 years of age ^[@r04],[@r10]^

The diagnosis of MTS is eminently clinical, corroborated by exams such as immunohistochemistry and molecular analysis. Since the first publications reporting the detection of repairing enzymes through the immunohistochemical method, loss of *MLH1* and *MSH2* expression was observed in colorectal carcinomas with microsatellite instability. Despite the micro-satellite instability detected through PCR remaining as standard methodology, the employment of immunohistochemistry in literature has expanded. ^[@r08],[@r10]^

Analogous to this, the immunohistochemical study with antibodies against repair proteins *MSH2*, *MLH1* and *MSH6* is currently the accepted method for evaluation of the function of these proteins in sebaceous neoplasms. The lack of nuclear immunoreactivity in tumor cells suggests MTS and has shown good correlation of this finding with microsatellite instability when compared to gold-standard tests. ^[@r08]^

Mathiak *et al* emphasize that the repair enzymes express themselves properly in sporadic cases of sebaceous carcinoma, which reinforces even further the role of immunohistochemistry in the characterization of MTS.^[@r06]^

Therefore, immunohistochemistry presents applicability in clinical practice as an element of identification of neoplasms, which carry deficiency in the activity of repair enzymes and phenotype of microsatellite instability. It is outstanding for MTS confirmation, as it is more accessible and less costly than molecular analysis, allied to its high positive predictive value. ^[@r06]^

When suspicious of MTS, the dermatologist may proceed with an immunohistochemical study of sebaceous tumors, if molecular analysis is not available to confirm the disease, thus allowing secondary prevention of visceral tumors. In our case, the absence of repair enzymes *MSH2* and *MSH6* in the immunohistochemical study reiterated the diagnosis of MTS and triggered a series of propedeutic actions, aiming for early diagnosis of morbidities and genetic counseling.
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